Estrogen Protects Neurotransmission Transcriptome During Status Epilepticus

Area of Science:

• Neuroscience
• Endocrinology
• Genomics

Background:

• Women with epilepsy often experience early menopause, leading to decreased estrogen levels.
• Lower estrogen is linked to neurodegeneration and cognitive decline.
• Estradiol (E2) replacement previously showed neuroprotective effects against seizure damage in rats.

Purpose of the Study:

• To investigate the protective mechanisms of E2 against transcriptomic alterations in the hippocampus following seizures.
• To understand how E2 influences genomic pathways of neurotransmission during status epilepticus (SE).

Main Methods:

• Used ovariectomized (OVX) female rats and kainic acid-induced SE.
• Administered E2 replacement therapy.
• Analyzed transcriptomic changes in the dentate gyrus (DG) using RNA sequencing.
• Performed Pathway Protection analysis and electrophysiological recordings for long-term potentiation (LTP).

Main Results:

• SE drastically altered 44% of DG genes without E2, impacting pathways like apoptosis, Alzheimer's disease, and neurotransmission.
• E2 replacement significantly reduced SE-affected genes to an average of 11%.
• E2 prevented SE-induced downregulation of synaptic receptor genes and protected key neurotransmission pathways (e.g., GABA, dopamine).
• E2-mediated estrogen signaling (ESG) genes buffered SE-induced alterations in neurotransmission, switching synergistic to antagonistic gene expression.
• LTP was preserved with E2 replacement, unlike in OVX rats without E2.

Conclusions:

• E2 replacement effectively mitigates SE-induced transcriptomic damage in the hippocampus.
• The estrogen signaling pathway acts as a genomic buffer, preserving neurotransmission and cognitive function (LTP) after SE.
• E2 therapy may be crucial for maintaining brain health in postmenopausal women with epilepsy.